Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, Jonathan E. Rosenberg, William Y. Kim et al.|New England Journal of Medicine|2024Cited by 145
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationX. Cynthia, Lisa A. Carey, Vera J. Suman et al.|JAMA Oncology|2024Cited by 20